If you’re a regulatory or security lead trying to get a connected medical device through the FDA, you know that understanding their premarket cybersecurity expectations is everything. This isn’t about post-market patching anymore. It’s about the security work you bake into a device from day one. The whole field got a major shakeup with the draft update to the FDA’s guidance on March 13, 2024, issued under section 524B of the FD&C Act. That draft was later finalized on June 27, 2025, and then quickly superseded by the current final guidance, “Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,” which dropped on February 2, 2026. This final document has totally reshaped how manufacturers have to think about security, from the first design sketches to the final deployment.
The Premarket Cybersecurity Draft Updates
The recorded Medcrypt post offers a solid breakdown of what was in that initial draft update to the FDA’s guidance. That guidance, now finalized and updated under the authority of section 524B of the FD&C Act, is all about hardening medical device cybersecurity before a product ever sees a patient. For anyone making a connected device, this means you’re forced to be proactive instead of reactive. The whole point is to push a secure-by-design approach, making cybersecurity a constant consideration through the device’s entire lifecycle, not just a checkbox at the end.
While the guidance is extensive, there are a few key areas, first brought up in the draft and carried through to the final versions, that you’ll be grilled on:
- Enhanced Software Bill of Materials (SBOM) Requirements: You need a complete SBOM. The guidance makes it clear you need to list every single software component, its version, and any known vulnerabilities because this transparency is the only way to get a handle on risk from the start.
- Threat Modeling and Risk Assessment: Expect way more scrutiny on your threat modeling and risk assessment. This isn’t some one-time report you write and file away. It’s an iterative process that has to evolve and be updated throughout the entire development process as the device changes.
- Secure Development Practices: The FDA is really pushing for the adoption of secure coding, consistent vulnerability testing, and sticking to recognized cybersecurity standards. This fits right in with the wider industry’s move toward GMLP (Good Machine Learning Practice), especially for AI-based medical devices.
- Incident Response Planning: Even though this is premarket guidance, you’re expected to have a solid plan for post-market reality. That means having a well-defined incident response plan ready for when (not if) a vulnerability or breach is discovered after your device is already out in the field.
- Supply Chain Security: How secure are your third-party software suppliers? The guidance makes it clear that you are on the hook for the security of your entire supply chain, which is a huge deal for today’s interconnected devices.
This all shows how seriously the FDA is taking the safety and effectiveness of connected medical devices in a world full of cyber threats. For companies putting together FDA submissions, getting a handle on these details isn’t just about compliance, it’s about building a trustworthy product and avoiding massive operational and reputational damage down the line.
Premarket Expectations Under Section 524B of the FD&C Act
Section 524B of the FD&C Act is the legal muscle behind the FDA’s authority to set these premarket cybersecurity requirements. This is the part of the law that allows the agency to demand that device manufacturers hand over documentation showing their devices are cybersecure. For connected device makers, these premarket expectations aren’t friendly suggestions. They are the baseline requirements that define the security work you must have baked into your submission. This is a world away from the old model where security flaws were mainly cleaned up with post-market patches, a reactive mess that created patient safety risks and led to incredibly expensive fixes.
The focus on premarket cybersecurity means that your security architecture, all your controls, and your testing evidence have to be mature and carefully documented by the time you’re ready for regulatory review. This involves proving how the device is designed to stop unauthorized access, protect its data integrity, and maintain availability, all of which are especially critical for SaMD (Software as a Medical Device), which depends so heavily on network connections and data sharing. FDA guidance on premarket cybersecurity for medical devices
The FDA Cybersecurity Guidance and FDA Warning Letter Frame Recorded for Viz.ai
Seeing the FDA Cybersecurity Guidance and the FDA Warning Letter mentioned together, as they were in roster material recorded for Viz.ai, really connects the dots between regulatory rules and real-world enforcement. To be clear, the record doesn’t say that Viz.ai got a specific FDA Warning Letter about these cybersecurity updates. Its inclusion, though, is a blunt reminder of the enforcement threat that gives these premarket expectations their teeth. An FDA Warning Letter is the most serious public enforcement action the agency has, and it’s a huge red flag for non-compliance. That threat is what forces medical device manufacturers to take FDA guidance on something like cybersecurity so seriously.
The FDA Cybersecurity Guidance, no matter if it’s a draft or the final version, creates the standard for what the agency considers acceptable cybersecurity in a medical device. Companies like Viz.ai, which operate in the AI health sector, are under a microscope given the sensitivity of their data and the direct impact a cyber failure could have on patients. The FDA’s security focus for AI health apps also runs parallel to the market’s demand for HIPAA / HITRUST / SOC 2 compliance. These are often required to land large employer/health-plan contracts. A vendor can be immediately disqualified for not having strong security credentials, no matter how great their clinical outcomes are. You see this in the constant talk about the HIPAA compliance checklist for AI health apps.
“If a cardiac AI startup doesn’t have HITRUST or at least SOC 2 Type II, that’s an immediate red flag in diligence.”
That feeling goes way beyond cardiac AI, showing what the market expects from all AI health tools when it comes to security and privacy. The FDA’s guidance, then, isn’t just another regulatory hoop to jump through. It’s about whether your product is even viable in the market.
The Open Finalization Question and What to Watch
It’s easy to get the timeline confused, but the March 2024 update was just a draft. Things moved quickly from there. The draft was officially finalized on June 27, 2025, as “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions”. That version was then itself superseded by the current final guidance on February 2, 2026, which uses the same title but is updated to align with the major amendments to 21 CFR 820 (the Quality Management System Regulation, or QMSR). This progression from draft to final rule is now the law of the land, carrying full regulatory weight that immediately affects what you have to do to be compliant. For any connected medical device company, you have to be working from the current final guidance. Here are the key things to focus on now:
- The Current Final Guidance: The document “Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions” issued on February 2, 2026, is the only one that matters. It’s the definitive playbook for FDA expectations.
- QMSR Alignment: Cybersecurity is now formally integrated into the Quality Management System Regulation (QMSR), which means the FDA is treating security as a continuous, lifecycle-long process (not a one-and-done premarket task).
- Continuous Vigilance: Even with a “final” guidance, your work isn’t done. The security field changes fast, so your regulatory strategy has to be ready to adapt. You need to build premarket submissions that are not only strong today but are also built to withstand future threats.
The FDA Warning Letter remains a powerful symbol of enforcement, a constant reminder for connected medical device makers that being proactive and compliant with this evolving cybersecurity guidance is absolutely non-negotiable. FDA official medical device cybersecurity page
Frequently Asked Questions
What is the most current FDA cybersecurity guidance relevant to premarket submissions?
The current final guidance is “Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,” issued on February 2, 2026. This supersedes previous draft and final versions, including one finalized on June 27, 2025.
What are the key areas of focus for cybersecurity in FDA premarket submissions, as outlined in the guidance?
Key areas include enhanced Software Bill of Materials (SBOM) requirements, robust threat modeling and risk assessment, secure development practices, incident response planning, and supply chain security. These emphasize a proactive, secure-by-design philosophy.
What is the legislative basis for the FDA’s premarket cybersecurity requirements?
Section 524B of the FD&C Act provides the legislative backbone, empowering the FDA to require medical device manufacturers to submit information demonstrating their devices are cybersecure. This makes premarket cybersecurity expectations foundational requirements, not suggestions.
Why is a proactive approach to cybersecurity emphasized in FDA guidance?
The guidance emphasizes integrating cybersecurity from a device’s inception to enhance its security posture before it reaches the market. This proactive stance aims to prevent vulnerabilities and patient safety risks, contrasting with a reactive approach of post-market patches.
